# The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude

> **NCT07517068** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of California, Riverside** · enrollment: 19 (actual)

## Conditions studied

- Hypoxemia
- Acute Mountain Sickness (AMS)
- Inflammation
- Immune Response

## Interventions

- **DRUG:** ACETAZOLAMIDE oral capsule
- **DEVICE:** Placebo Arm

## Key facts

- **NCT ID:** NCT07517068
- **Lead sponsor:** University of California, Riverside
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-17
- **Primary completion:** 2026-06-15
- **Final completion:** 2026-12-15
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07517068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07517068, "The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07517068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*